Study On Level Of IL-12/IFN-γ In Serum Of Mycobacterium Tuberculosis MPT-64 Recombinant Adenovirus Vaccine

Object:To study the immunogenicity and protective efficacy of Mycobacterium tuberculosis MPT64 gene recombinant adenovirus vaccine, and provide a theoretical basis for the study of new tuberculosis vaccines.Methods:50 female C57BL/6 mice were randomly divided into 5 groups.Group A and B were immunized with the saline;Group C with empty adenovirus vector;Group D with Mycobacterium tuberculosis MPT-64 recombinant adenovirus vaccine; Group E with BCG. Except Group E, all the other four groups were respectively immunized with the interval of 2 weeks, altogether for three times.4 weeks after the last immunization,four mice were chosen randomly from each group, levels of IFN-γand IL-12 serum and MPT64-specific antibody were tested by ELISA assay.For the rest mice,except Group A,were all infected with 5×10 ^ 6CFU Mycobacterium tuberculosis strains H37Rv through the tail vein.4 weeks later, levels of IFN-γand IL-12 serum and MPT64-specific antibody were tested by ELISA assay.Results:Mycobacterium tuberculosis MPT-64 recombinant adenovirus vaccine could stimulate higher level of MPT64-specific antibody which was significantly different with the other groups.Levels of IFN-γand IL-12 serum in Group D were significantly higher than Group A,B and C,but without significant differernce with Group E.Conclusion:Preliminary results show that:Mycobacterium tuberculosis MPT64 recombinant adenovirus vaccine has strong immunogenicity against Mycobacterium tuberculosis challenge,which was equivalent to the protective effect of BCG. It can be taken as one of the candidate vaccine.